Key facts
- NeuroEM Therapeutics’s last known valuation is $17.0M (Aug 2025).
- It has raised $6.2M across 2 recorded rounds; the latest was Seed Round ($1.9M) in Apr 2025.
- Notable investors include National Institutes of Health, Tampa Bay Wave, New York Angels, BlueLake Ventures, Lunch Pail Ventures — 8 tracked in total.
- NeuroEM Therapeutics has filed 2 Form Ds with the SEC since 2024, most recently Apr 2025 ($1.9M sold to 23 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for NeuroEM Therapeutics
Funding rounds
2 roundsAbout NeuroEM Therapeutics
Developer of a medical device system designed to combat cognitive impairment caused by neurodegenerative conditions. The company's device targets specific regions of the brain affected by Alzheimer's disease, breaking down beta-amyloid and p-tau proteins using transcranial electromagnetic treatment leveraging radio frequencies, enabling healthcare professionals to slow or potentially stop the progression of cognitive challenges.
- Sector
- Healthcare
- HQ
- Tampa, FL, United States
- Founded
- 2013
- Employees
- 6
- Website
- neuroem.com/
- Ownership
- Privately Held (backing)
NeuroEM Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroEM Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroEM Therapeutics in its N-PORT filings yet. We sweep new filings monthly.